Evidence & concentration worksheet · Metabolic & Weight Loss
Semaglutide 20 mg
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
Evidence review
Approved dosing is product-specific
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
How it works
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone involved in glucose regulation and appetite.[1] Structural modifications, including a fatty-acid side chain that promotes albumin binding and resistance to enzymatic breakdown, extend its half-life and support once-weekly dosing for approved injectable products.[7]
FDA-approved semaglutide products include Ozempic, Rybelsus, and Wegovy, each with product- and indication-specific labeling.[2][3][4] By 2026, Wegovy labeling included multiple injection presentations, an oral tablet presentation, cardiovascular-risk reduction, and an accelerated-approval indication for specified adults with noncirrhotic MASH and F2–F3 fibrosis; Wegovy HD added a 7.2 mg injection presentation.[3][23][24] None of this makes an unverified research powder equivalent to an approved product.
Benefits & side effects
Semaglutide has a large human evidence base across diabetes, weight management, and cardiovascular outcomes. STEP 1 found greater mean weight reduction with semaglutide 2.4 mg than placebo over 68 weeks, while SELECT found fewer major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes.[9][13]
SUSTAIN-6 reported fewer cardiovascular events in people with type 2 diabetes at high cardiovascular risk.[11] Results remain population-, formulation-, and dose-specific, and a randomized withdrawal study found weight regain after semaglutide discontinuation.[22]
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- PubChem — Semaglutide compound summary (2026)
- U.S. FDA — Ozempic approval and current labeling (2026)
- U.S. FDA — Current Wegovy prescribing information (2026)
- U.S. FDA — Rybelsus approval and current labeling (2026)
- U.S. FDA — Concerns with unapproved GLP-1 drugs used for weight loss (2026)
- Journal of Medicinal Chemistry — Discovery of the once-weekly GLP-1 analogue semaglutide (2015)
- Cell Metabolism — Mechanisms and therapeutic application of GLP-1 (2018)
- New England Journal of Medicine — STEP 1 semaglutide obesity trial (2021)
- New England Journal of Medicine — SUSTAIN-6 cardiovascular outcomes trial (2016)
- New England Journal of Medicine — SELECT cardiovascular outcomes trial (2023)
- European Medicines Agency — Wegovy European public assessment report (2026)
- U.S. FDA — Dosing errors with compounded injectable semaglutide (2024)
- JAMA — Semaglutide withdrawal and weight-loss maintenance (2021)
- U.S. FDA — 2026 approval of higher-dose Wegovy injection (2026)
- U.S. FDA — Wegovy indication for MASH with fibrosis (2025)
- U.S. FDA — Proposed exclusion of semaglutide and tirzepatide from the 503B bulks list (2026)
Other vial sizes